Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group
暂无分享,去创建一个
Kenneth C. Anderson | Benjamin Djulbegovic | Bart Barlogie | Paul G. Richardson | Gareth J. Morgan | Mario Boccadoro | Rafael Fonseca | Heinz Ludwig | Keith Wheatley | Robert A. Kyle | R. Bataille | B. Barlogie | K. Anderson | G. Morgan | M. Dimopoulos | P. Sonneveld | R. Fonseca | J. Miguel | B. Ness | P. Richardson | G. Tricot | M. Drayson | M. Oken | M. Boccadoro | B. Djulbegovic | G. Gahrton | W. Dalton | R. Kyle | P. Greipp | D. Harrington | B. Sirohi | H. Ludwig | D. Vesole | J. Harousseau | I. Turesson | J. Westin | B. Durie | J. Bladé | J. Child | R. Powles | K. Shimizu | C. Shustik | K. Wheatley | D. Weber | D. Joshua | William S. Dalton | Pieter Sonneveld | W. Bensinger | Joan Bladé | Gösta Gahrton | Jean-Luc Harousseau | Martin M. Oken | Guido Tricot | David Roodman | Brian G. M. Durie | Philip R. Greipp | Régis Bataille | Jan Westin | Ingemar Turesson | Mark Drayson | T. Facon | M. Hussein | D. Roodman | Mohamad A. Hussein | Bhawna Sirohi | Meletios A. Dimopoulos | William Bensinger | David H. Vesole | J. Anthony Child | Thiery Facon | David P. Harrington | Douglas E. Joshua | R. L. Powles | Jesús F. San Miguel | Kazuyuki Shimizu | Chaim Shustik | Brian G Van Ness | Donna M. Weber | K. Anderson
[1] R. Kyle,et al. "Idiopathic" Bence Jones proteinuria: long-term follow-up in seven patients. , 1982, The New England journal of medicine.
[2] Joan,et al. Immunophenotypic characterization of plasma cells from monoclonal gammopathy of undetermined significance patients. Implications for the differential diagnosis between MGUS and multiple myeloma. , 1998, The American journal of pathology.
[3] R. Casale,et al. The natural history of monoclonal gammopathy of undetermined significance. A 5- to 20-year follow-up of 263 cases. , 1997, Acta haematologica.
[4] A. Órfão,et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. , 1999, Blood.
[5] M. Gobbi,et al. Nonsecretory multiple myeloma. Presenting findings, clinical course and prognosis. , 1985, Acta haematologica.
[6] R A Kyle,et al. "Benign" monoclonal gammopathy--after 20 to 35 years of follow-up. , 1993, Mayo Clinic proceedings.
[7] C. Klersy,et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] R. Kyle,et al. Smoldering multiple myeloma. , 1980, The New England journal of medicine.
[9] R A Kyle,et al. Retrospective cohort study of 148 patients with polyclonal gammopathy. , 2001, Mayo Clinic proceedings.
[10] L. Elveback,et al. Incidence of monoclonal proteins in a Minnesota community with a cluster of multiple myeloma. , 1972, Blood.
[11] Terry M Therneau,et al. A long-term study of prognosis in monoclonal gammopathy of undetermined significance. , 2002, The New England journal of medicine.
[12] A. Bezjak,et al. Solitary plasmacytoma treated with radiotherapy: impact of tumor size on outcome. , 2001, International journal of radiation oncology, biology, physics.
[13] R. Kyle,et al. Monoclonal gammopathy of undetermined significance and smouldering multiple myeloma: emphasis on risk factors for progression , 2007, British journal of haematology.
[14] U. Axelsson,et al. Frequency of pathological proteins (M-components) om 6,995 sera from an adult population. , 2009, Acta medica Scandinavica.
[15] A. López-Guillermo,et al. Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance , 1992, British journal of haematology.
[16] J. Cox,et al. Persistence of myeloma protein for more than one year after radiotherapy is an adverse prognostic factor in solitary plasmacytoma of bone , 2002, Cancer.
[17] M. Dimopoulos,et al. Solitary plasmacytoma of bone and asymptomatic multiple myeloma. , 1992, Hematology/oncology clinics of North America.
[18] N. Güler,et al. Extramedullary plasmacytoma , 2000 .
[19] G. Morgan,et al. The interleukin-6 receptor alpha-chain (CD126) is expressed by neoplastic but not normal plasma cells. , 2000, Blood.
[20] M. Drayson,et al. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. , 2001, Blood.
[21] M. Vicariot,et al. Monoclonal gammopathies in the adult population of Finistère, France. , 1982, Journal of clinical pathology.
[22] R. Kyle,et al. Plasma cell leukemia: an evaluation of response to therapy. , 1987, The American journal of medicine.
[23] J. Laredo,et al. Magnetic Resonance Appearance of Monoclonal Gammopathies of Unknown Significance and Multiple Myeloma , 1997, Spine.
[24] M. Björkholm,et al. Blood clonal B‐cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): association with malignant transformation , 1996, British journal of haematology.
[25] M. Gobbi,et al. Nonsecretory Multiple Myeloma , 1985 .
[26] L. Baldini,et al. Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. , 1996, Blood.
[27] H. Cohen,et al. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. , 1998, The American journal of medicine.
[28] R. Kyle,et al. Sequence of testing for monoclonal gammopathies. , 2009, Archives of pathology & laboratory medicine.
[29] R. Kyle,et al. Monoclonal gammopathy of undetermined significance. Natural history in 241 cases. , 1978, The American journal of medicine.
[30] U. Axelsson. A 20-year follow-up study of 64 subjects with M-components. , 2009, Acta medica Scandinavica.
[31] N. Güler. Extramedullary plasmacytoma: tumor occurrence and therapeutic concepts. , 2000, Cancer.
[32] J. Cox,et al. Solitary bone plasmacytoma: outcome and prognostic factors following radiotherapy. , 1998, International journal of radiation oncology, biology, physics.
[33] J. Katzmann,et al. Serum Reference Intervals and Diagnostic Ranges for Free κ and Free λ Immunoglobulin Light Chains: Relative Sensitivity for Detection of Monoclonal Light Chains , 2002 .
[34] S. Jagannath,et al. CRITERIA FOR EVALUATING DISEASE RESPONSE AND PROGRESSION IN PATIENTS WITH MULTIPLE MYELOMA TREATED BY HIGH‐DOSE THERAPY AND HAEMOPOIETIC STEM CELL TRANSPLANTATION , 1998, British journal of haematology.
[35] J T Whicher. The Monoclonal Gammopathies, Multiple Myeloma and Related Plasma-Cell Disorders , 1977 .